[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 700, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith M.D., Ph.D.", "age": 62, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1347967, "exercisedValue": 10163472, "unexercisedValue": 51843852}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 725633, "exercisedValue": 849639, "unexercisedValue": 2896538}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 897933, "exercisedValue": 3021392, "unexercisedValue": 16625696}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 63, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 951933, "exercisedValue": 4257259, "unexercisedValue": 11511893}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 54, "title": "Executive Vice President of Development", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 701200, "exercisedValue": 0, "unexercisedValue": 13540803}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 43, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 49.68, "open": 52.76, "dayLow": 52.4, "dayHigh": 56.08, "regularMarketPreviousClose": 49.68, "regularMarketOpen": 52.76, "regularMarketDayLow": 52.4, "regularMarketDayHigh": 56.08, "payoutRatio": 0.0, "beta": 1.264, "forwardPE": -13.358024, "volume": 4556850, "regularMarketVolume": 4556850, "averageVolume": 2047031, "averageVolume10days": 2187450, "averageDailyVolume10Day": 2187450, "bid": 50.06, "ask": 57.75, "bidSize": 2, "askSize": 2, "marketCap": 10113085440, "fiftyTwoWeekLow": 29.17, "fiftyTwoWeekHigh": 62.4, "allTimeHigh": 62.4, "allTimeLow": 14.08, "fiftyDayAverage": 42.3358, "twoHundredDayAverage": 39.957874, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 8108701696, "profitMargins": 0.0, "floatShares": 158526822, "sharesOutstanding": 186933190, "sharesShort": 17968076, "sharesShortPriorMonth": 16527230, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.096099995, "heldPercentInsiders": 0.0199, "heldPercentInstitutions": 1.03906, "shortRatio": 7.99, "shortPercentOfFloat": 0.102299996, "impliedSharesOutstanding": 191852484, "bookValue": 9.981, "priceToBook": 5.4202986, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -812060032, "trailingEps": -4.52, "forwardEps": -4.05, "enterpriseToEbitda": -9.104, "52WeekChange": 0.13298428, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 54.1, "targetHighPrice": 99.0, "targetLowPrice": 64.0, "targetMeanPrice": 76.33333, "targetMedianPrice": 75.0, "recommendationMean": 1.26316, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 18, "totalCash": 2137170944, "totalCashPerShare": 11.433, "ebitda": -890700032, "totalDebt": 132787000, "quickRatio": 11.581, "currentRatio": 11.794, "debtToEquity": 7.119, "returnOnAssets": -0.26472, "returnOnEquity": -0.46613997, "grossProfits": -604710016, "freeCashflow": -396289984, "operatingCashflow": -684900992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Revolution Medicines, Inc.", "longName": "Revolution Medicines, Inc.", "regularMarketPrice": 54.1, "exchange": "NMS", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 8.89694, "corporateActions": [], "postMarketTime": 1760744923, "regularMarketTime": 1760731200, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "postMarketChangePercent": 0.277267, "postMarketPrice": 54.25, "postMarketChange": 0.150002, "regularMarketChange": 4.42, "regularMarketDayRange": "52.4 - 56.08", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2047031, "fiftyTwoWeekLowChange": 24.929998, "fiftyTwoWeekLowChangePercent": 0.85464513, "fiftyTwoWeekRange": "29.17 - 62.4", "fiftyTwoWeekHighChange": -8.300003, "fiftyTwoWeekHighChangePercent": -0.13301286, "fiftyTwoWeekChangePercent": 13.298428, "earningsTimestamp": 1754510400, "earningsTimestampStart": 1762372800, "earningsTimestampEnd": 1762372800, "earningsCallTimestampStart": 1754512200, "earningsCallTimestampEnd": 1754512200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -4.52, "epsForward": -4.05, "epsCurrentYear": -5.30678, "priceEpsCurrentYear": -10.194506, "fiftyDayAverageChange": 11.764198, "fiftyDayAverageChangePercent": 0.27787825, "twoHundredDayAverageChange": 14.142124, "twoHundredDayAverageChangePercent": 0.35392582, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "displayName": "Revolution Medicines", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]